FDA Inspection 1086635 — Apex Pharmaceuticals Inc.

Apex Pharmaceuticals Inc. — FEI 3006719767

The FDA completed an inspection of Apex Pharmaceuticals Inc. on Apr 18, 2019 in South Plainfield, NJ. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 3 citations were issued during this inspection. Product area: Drugs.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Apr 18, 2019
Fiscal Year
2019
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
South Plainfield, NJ (United States)

Citations

IDCFRDescription
113321 CFR 211.25(a)GMP Training Frequency
121321 CFR 211.67(a)Cleaning / Sanitizing / Maintenance
360321 CFR 211.160(b)Scientifically sound laboratory controls

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.